SCHEMBL115682

SCHEMBL115682

CC(C)(C)OC(=O)N1CC=C(c2ccccc2-c2cnc(N3CCOCC3)nc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDK4 Q16654 1/20 0.54
BTK Q06187 1/20 0.49
GRM5 P41594 7/20 0.47
GRM1 Q13255 6/20 0.47
NAMPT P43490 1/20 0.46
HTR6 P50406 1/20 0.46
EED O75530 2/20 0.46
RBBP4 Q09028 2/20 0.46
SUZ12 Q15022 2/20 0.46
EZH2 Q15910 2/20 0.46
KIT P10721 1/20 0.45
PIK3R1 P27986 3/20 0.44
PIK3CA P42336 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15000447 0.89 CYP11B2 (0.49) PDK4GRM5GRM1NAMPTKIT
SCHEMBL23210198 0.79 PDK4 (0.63) PDK4BTKGRM5GRM1NAMPT
SCHEMBL22324934 0.78 GPR119 (0.55) PDK4GRM5GRM1NAMPTHTR6
SCHEMBL13077670 0.77 NAMPT (0.44) NAMPTEEDRBBP4SUZ12EZH2
SCHEMBL3732875 0.76 CXCR3 (0.48) NAMPTEEDRBBP4SUZ12EZH2
SCHEMBL252383 0.76 BTK (0.47) PDK4BTKGRM5GRM1HTR6
SCHEMBL23228627 0.75 PDK4 (0.59) PDK4BTKGRM5GRM1NAMPT
SCHEMBL18129626 0.75 MAP4K1 (0.54) BTKKIT
SCHEMBL16639119 0.75 PIK3CA (0.54) BTKPIK3R1PIK3CA
SCHEMBL3436385 0.75 PDK4 (0.69) PDK4GRM5GRM1NAMPTHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424840-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-08-06 EP disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
EP-2424840-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 PDK4 1854/4885BTK 695/4885GRM5 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.